OROXCELL
SAS Created:
2004 Headcount:
24
THE
ORGANIZATION
Executive
Management
·
Jean PACHOT, President & C.S.O.
·
Christophe DINI, Vice President and Chemical & Physical
Sciences Director
·
Jacques BITON.Vice President and Life Sciences Director.
Funding
history
·
OROXCELL is a successful French Spin-Off of Sanofi Aventis founded
by three experienced senior scientists who jointly own 100 % of that
independent and privately-owned CRO.
·
OROXCELL has been recognized as an innovative new company by the
distinguished ANVAR 2004 award.
The
French Senate has named Jean PACHOT, the CEO and CSO to be one of the most
innovative young entrepreneurs of 2005.
·
OROXCELL received the Label of “Jeune Entreprise Innovante”
(“Innovative New Company”) from the French Ministry of Research and is
a member of the progressive group “Ile de France Meditech Santé”.
A
year after its creation, OROXCELL employs 24 staff
More
than 30 contracts have been signed with a range of Pharmaceutical and Life
Sciences companies.
Organization
profile
OROXCELL
is a leading French CRO focusing on the bioavailability of compounds
issuing from life sciences.
The
company has extensive expertise in both innovative formulations for oral
absorption, and new in vitro technologies to evaluate ADME parameters,
physico-chemistry, bioanalysis and molecular pharmaceutics.
OROXCELL
offers, through patented formulation technologies, real opportunities to
add value to life sciences products.
Founded
mid 2004, OROXCELL, award-winning for its innovation, is a unique
“one-stop shopping” platform which covers a broad spectrum of
technologies allowing its partners to reach their scientific and economic
goals readily.
1.
PRE-CLINICAL CROS
CONTACT:
o
JEAN
PACHOT /// jean.pachot@oroxcell.com
ADDRESS
:
o
PARC
BIOCITECH - 102, ROUTE DE NOISY, 93230 ROMAINVILLE, FR
ACTIVITIES
Technology
overview / Expertise areas / Trade marks
Caco-2,
P-gp interaction, metabolic stability (S9, microsomes, hepatocytes), Cyp
inhibition, induction, Log P, Log D, pKa, LCMS, LCMSMS, LCUV,
radioactivity, PK in rodents, tissue distribution.
Products
and services
•
ADME Screening and profiling,
•
Pre-clinical PK studies,
•
Formulation, bioanalysis,
•
Physico-chemical determination,
•
Stability testing.
Partners
Anaconda,
Cellial, Euroscreen, Galderma, Guerbet, IPSEN,
L’Oréal,
Sanofi aventis, Servier, Institut de Recherche Pierre Fabre,
Urogene,
Theraptosis.
Aeras
of potential collaboration / Opportunities
Lead
optimization, drug candidate selection, formulation, oral absorption
improvement,
ADME and Physico-chemistry determination, rescue projects
return
on the top.
